Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Fig. 4

Direct adjusted survival probability for PFS (a) and OS (b) from multivariable Cox models. For different risk categories we used the combination of the basal values of LDH and the ΔNLR for PFS, and the combination of basal values of LDH and Δlymphocytes for OS. 3a For ∆NLR > 0.86 and basal LDH ≥ ULN the median PFS was 5 months; for ∆NLR > 0.86 and basal LDH < ULN the median PFS was 5 months; for ∆NLR ≤ 0.86 and basal LDH ≥ ULN the median PFS was 7 months; for ∆NLR ≤ 0.86 and basal LDH < ULN the median PFS was 20 months. 3b) For ∆lymphocytes < − 300 and basal LDH ≥ ULN the median OS was 11 months; for ∆lymphocytes ≥ − 300 and basal LDH ≥ ULN the median OS was 20 months; for ∆lymphocytes < − 300 and basal LDH < ULN the median OS was 28 months; for ∆lymphocytes ≥ − 300 and basal LDH < ULN the median OS was 52 months

Back to article page